TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3067408

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate standard tablets (nitrosorbide-NS) at a dose of 10 mg per os
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Sublingual NS administration
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate prolonged action isomac-retard containing 40 mg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dinitrosorbilong (DNL) for gingival application
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Increased NS dose per os
Number of subjects: 28
Study: 29179016

Group type: EXPERIMENTAL
Intervention: Group family-based cognitive behavioral therapy (GF-CBT)
Number of subjects: 85
Study: 25743819

Group type: EXPERIMENTAL
Intervention: EAAL treatment group
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 23054940

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (increased minutes of physical activity over 12 months)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Higher cardiovascular fitness and more physical activity (self-reported)
Number of subjects: 64
Study: 21915515

Group type: EXPERIMENTAL
Intervention: FL‐ Fluorniz (n=24)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DUO ‐ Duofluorid XII (n=22)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: DF ‐ Durafluor (n=21)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All varnishes
Number of subjects: 36
Study: 18174447

Group type: EXPERIMENTAL
Intervention: Modified constraint-induced therapy (mCIT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Time-matched exercise program
Number of subjects: 35

Group type: COMPARATOR
Intervention: No-treatment control regimen
Number of subjects: 35
Study: 16340597

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (5 U)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 31
Study: 14626260

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 0

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 0
Study: 10907099

Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with threatening feedback on important behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with threatening feedback on important behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with bolstering feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with bolstering feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High intrinsic religious orientation with threatening feedback on unimportant behavior
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low intrinsic religious orientation with threatening feedback on unimportant behavior
Number of subjects: 0
Study: 8850397

Group type: EXPERIMENTAL
Intervention: PGE1 (30 ng/kg/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 19
Study: 1320916

Group type: EXPERIMENTAL
Intervention: Granisetron (40 micrograms/kg)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Alizapride (12 mg/kg) plus Dexamethasone (8 mg)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Metoclopramide (7 mg/kg) plus Dexamethasone (12 mg)
Number of subjects: 340
Study: 6375273

Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose heparin 5000 IU every 12 hours
Number of subjects: 64

Group type: COMPARATOR
Intervention: TED stocking (Kendall Co.)
Number of subjects: 64
Study: 30415432

Group type: EXPERIMENTAL
Intervention: Immediate ART irrespective of CD4 count offered from the trial-start in 2014
Number of subjects: 0
Study: 29686818

Group type: EXPERIMENTAL
Intervention: ALS‐EP (specific exercise programme based on moderate aerobic workout and isometric contractions)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard neuromotor rehabilitation treatment
Number of subjects: 38
Study: 26725544

Group type: EXPERIMENTAL
Intervention: Opicapone 50 mg
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Opicapone 25 mg
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Opicapone 5 mg
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: Entacapone
Number of subjects: 590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 590
Study: 24647464

Group type: EXPERIMENTAL
Intervention: Trial participants (n = 1325)
Number of subjects: 1325

Group type: COMPARATOR
Intervention: General population patients (n = 1056)
Number of subjects: 1325
Study: 22710266

Group type: EXPERIMENTAL
Intervention: Goal of near‐maximal stroke volume guided by oesophageal Doppler (D group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Goal of zero balance and normal bodyweight (Z group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Both groups (D and Z)
Number of subjects: 150
Study: 20032478

Group type: EXPERIMENTAL
Intervention: Quercetin 150 mg/d
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 19127916

Group type: EXPERIMENTAL
Intervention: Acupoint catgut embedding
Number of subjects: 2

Group type: COMPARATOR
Intervention: Electroacupuncture
Number of subjects: 2
Study: 15795570

Group type: EXPERIMENTAL
Intervention: Trochanteric Gamma nail
Number of subjects: 210

Group type: COMPARATOR
Intervention: Compression hip screw
Number of subjects: 210
Study: 11552015

Group type: EXPERIMENTAL
Intervention: 10,000 IU IFN-alpha2a ingested on alternate days for 9 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 30,000 IU IFN-alpha2a ingested on alternate days for 9 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9661845

Group type: EXPERIMENTAL
Intervention: Group I (n = 20) with marked external tibial torsion, TFA > or = 20 degrees
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group II (n = 20) with TFA between 10 and 20 degrees
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (20 normal limbs with TFA = 10 degrees)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group I limbs compared to Group II limbs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group I limbs
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Group II limbs
Number of subjects: 25
Study: 8057631

Group type: EXPERIMENTAL
Intervention: Post-compliance touch
Number of subjects: 198

Group type: COMPARATOR
Intervention: Nontouched subjects
Number of subjects: 198
Study: 3185464

Group type: EXPERIMENTAL
Intervention: Zolpidem (hypnotic)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31808520

Group type: EXPERIMENTAL
Intervention: Cryoablation for persistent AF
Number of subjects: 609
Study: 30715535

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg Se from SY
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg Se from SY
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: 3.0 mg/kg Se from SY
Number of subjects: 768

Group type: COMPARATOR
Intervention: 0 mg/kg Se from SY (basal diet)
Number of subjects: 768
Study: 27838474

Group type: EXPERIMENTAL
Intervention: Personalized AHFS treatments (specific treatments not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment with intravenous diuretics (control group)
Number of subjects: 0
Study: 26119273

Group type: COMPARATOR
Intervention: ICD‐9 codes for mortality model
Number of subjects: 244704

Group type: COMPARATOR
Intervention: ICD‐9 codes for hospital length of stay (HLOS) model
Number of subjects: 244704

Group type: COMPARATOR
Intervention: ICD‐9 codes for intensive care unit length of stay (ILOS) model
Number of subjects: 244704
Study: 23612942

Group type: EXPERIMENTAL
Intervention: Couple-based HIV prevention intervention
Number of subjects: 728
Study: 21500574

Group type: EXPERIMENTAL
Intervention: Mobile-bearing prosthesis
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fixed-bearing prosthesis
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 72
Study: 19681773

Group type: EXPERIMENTAL
Intervention: GlideScope Ranger video laryngoscope
Number of subjects: 8

Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 8
Study: 17207684

Group type: EXPERIMENTAL
Intervention: Postural control training with external focus of attention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Postural control training with internal focus of attention
Number of subjects: 40
Study: 15176647

Group type: COMPARATOR
Intervention: A6 15 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 35 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 75 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 150 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 300 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 35 mg repeated doses
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 75 mg repeated doses
Number of subjects: 26

Group type: COMPARATOR
Intervention: A6 150 mg repeated doses
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11533546

Group type: EXPERIMENTAL
Intervention: Intravenous liposomal amphotericine B + oral itraconazole
Number of subjects: 88

Group type: COMPARATOR
Intervention: Intravenous fluconazole + oral itraconazole
Number of subjects: 88
Study: 9683361

Group type: EXPERIMENTAL
Intervention: Prednisone 40 mg/day
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 7851235

Group type: EXPERIMENTAL
Intervention: Capillary blood glucose monitoring (CBGM) using AccuChek II blood glucose meter
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Capillary blood glucose monitoring (CBGM) using visual and manual interpretation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Capillary blood glucose monitoring (CBGM)
Number of subjects: 80
Study: 3141293

Group type: EXPERIMENTAL
Intervention: MCT/LCT emulsion
Number of subjects: 14

Group type: COMPARATOR
Intervention: LCT exclusively
Number of subjects: 14
Study: 31595803

Group type: EXPERIMENTAL
Intervention: Medication usage recorded as a treatment for nausea AEs (76% of cases)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Platelet transfusions provided for thrombocytopenia AEs (24% of cases)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nausea AEs
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Thrombocytopenia AEs
Number of subjects: 101
Study: 29578944

Group type: EXPERIMENTAL
Intervention: PF‐05089771 150 mg twice daily
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg twice daily
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study: 28424870

Group type: EXPERIMENTAL
Intervention: Concurrent high-intensity interval training (CT)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Resistance training (RT)
Number of subjects: 16
Study: 26040644

Group type: EXPERIMENTAL
Intervention: Electronic patient-held portable health file (PHF) added to usual care
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Paper patient-held portable health file (PHF) added to usual care
Number of subjects: 792

Group type: COMPARATOR
Intervention: Usual care alone (no PHF)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 792
Study: 22983355

Group type: EXPERIMENTAL
Intervention: (18)FDG PET-guided rTMS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard anatomically guided rTMS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 15
Study: 23511042

Group type: EXPERIMENTAL
Intervention: Yoga with counselling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Only counselling
Number of subjects: 60
Study: 20128424

Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16703624

Group type: COMPARATOR
Intervention: 30% perioperative oxygen
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 80% perioperative oxygen
Number of subjects: 45
Study: 15657474

Group type: COMPARATOR
Intervention: CAF (5 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CAF (3 mg/kg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CAF (7 mg/kg)
Number of subjects: 13
Study: 11377115

Group type: EXPERIMENTAL
Intervention: PSA screening with or without DRE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8913208

Group type: COMPARATOR
Intervention: Volume control ventilation with a square flow waveform
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Volume control with a decelerating flow waveform
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Pressure control ventilation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Volume control ventilation with a decelerating flow waveform
Number of subjects: 25
Study: 2082718

Group type: EXPERIMENTAL
Intervention: Dydrogesterone (20 mg/day during the last 12 days of the menstrual cycle)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 299221

Group type: EXPERIMENTAL
Intervention: Chemo-Immunotherapy consisting of 5-Fluorouracil and CCNU and Corynebacterium parvum administered intermittently for one year.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31782768

Group type: EXPERIMENTAL
Intervention: 9 × 105 PfSPZ Vaccine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 1.8 × 106 PfSPZ Vaccine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study: 31505943

Group type: EXPERIMENTAL
Intervention: Customized insole with metatarsal and arch support
Number of subjects: 72

Group type: COMPARATOR
Intervention: Flat insole (control)
Number of subjects: 72
Study: 28158901

Group type: EXPERIMENTAL
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 163

Group type: COMPARATOR
Intervention: 180° anterior fundoplication
Number of subjects: 163
Study: 26179504

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times per day for 3 days before surgery)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (three times per day for 3 days before surgery)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 24281386

Group type: EXPERIMENTAL
Intervention: 7T SWI
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 3T SWI
Number of subjects: 10
Study: 21786271

Group type: EXPERIMENTAL
Intervention: Etoricoxib 120 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 20814332

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (MPH)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study: 17906207

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 during 24 hours (arm 1)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Paclitaxel 120 mg/m2 during 96 hours (arm 2)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 140
Study: 16244050

Group type: EXPERIMENTAL
Intervention: Waiving the 100-hour rule
Number of subjects: 0

Group type: COMPARATOR
Intervention: 100-hour rule (control)
Number of subjects: 0
Study: 11849578

Group type: EXPERIMENTAL
Intervention: Halothane (H)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Sevoflurane (S)
Number of subjects: 420
Study: 10094751

Group type: EXPERIMENTAL
Intervention: High-pressure capnoperitoneum (15 mmHg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-pressure capnoperitoneum (7 mmHg)
Number of subjects: 20
Study: 8703860

Group type: EXPERIMENTAL
Intervention: 6 mm treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5 mm treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Multizone treatment
Number of subjects: 100
Study: 1306051

Group type: EXPERIMENTAL
Intervention: Fentanyl (3 micrograms.kg‐1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.6 microgram.kg‐1)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no opioid)
Number of subjects: 9
Study: 6389559

Group type: EXPERIMENTAL
Intervention: Keller's operation modified by Kirschner‐wire distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Keller's operation
Number of subjects: 0
Study: 31686109

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant glycoprotein E herpes zoster vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30354701

Group type: EXPERIMENTAL
Intervention: Qigong exercise (QE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Stress management (SM)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 26657263

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection with betamethasone
Number of subjects: 74

Group type: COMPARATOR
Intervention: Oral NSAIDs
Number of subjects: 74
Study: 25000552

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin plus fluocinolone acetonide
Number of subjects: 590

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 590
Study: 21508180

Group type: EXPERIMENTAL
Intervention: Propafenone 150 mg 3 times daily with quinidine 100 mg twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Propafenone 150 mg 3 times daily with placebo
Number of subjects: 102
Study: 19171275

Group type: EXPERIMENTAL
Intervention: Endoscopic iliopsoas tendon release at the lesser trochanter
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Endoscopic transcapsular psoas release from the peripheral compartment
Number of subjects: 19
Study: 17048115

Group type: EXPERIMENTAL
Intervention: Sorbitol (5 Gm)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Sorbitol (1.25 Gm or greater)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Sucrose (control)
Number of subjects: 44
Study: 15099876

Group type: EXPERIMENTAL
Intervention: filgrastim
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 11943790

Group type: EXPERIMENTAL
Intervention: Faecal occult blood screening (FOB) for colorectal cancer
Number of subjects: 2184

Group type: EXPERIMENTAL
Intervention: Anxiety levels measured using the Spielberger anxiety inventory (SAI) in 100 test positive patients
Number of subjects: 2184
Study: 12511809

Group type: EXPERIMENTAL
Intervention: Active medication (buspirone or fluoxetine)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Higher predisposition toward action
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Precontemplation, contemplation, and maintenance scores
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Married or cohabiting status
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Readiness for action measure
Number of subjects: 113
Study: 7622822

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) in placebo controlled trials
Number of subjects: 67

Group type: COMPARATOR
Intervention: Tricyclic antidepressants (TCAs) in placebo controlled trials
Number of subjects: 67
Study: 2239377

Group type: EXPERIMENTAL
Intervention: Surgical technique exposing the conus medullaris through a T12-L1 laminectomy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Surgical technique exposing the dorsal roots distally in the cauda equina through a L2-L3 to S1 laminectomy
Number of subjects: 10
Study: 379932

Group type: EXPERIMENTAL
Intervention: Levamisole as adjunctive treatment between cycles of chemotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional high dose chemotherapy
Number of subjects: 60
Study: 31887090

Group type: EXPERIMENTAL
Intervention: AB‐ace (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with acepromazine [0.02 mg/kg])
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AB‐mid (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with midazolam [0.2 mg/kg])
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AB‐dex (alfaxalone [2 mg/kg] and butorphanol [0.4 mg/kg] combined with dexmedetomidine [0.005 mg/kg])
Number of subjects: 6
Study: 31438618

Group type: EXPERIMENTAL
Intervention: MegaSporeBiotic (Bacillus spp. spores) for 34 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rifaximin for 10 days followed by nutraceutical agent (G1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rifaximin for 10 days followed by low-FODMAP diet (G3)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MegaSporeBiotic (Bacillus spp. spores)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Rifaximin followed by nutraceutical or low-FODMAP diet
Number of subjects: 90
Study: 28944901

Group type: EXPERIMENTAL
Intervention: 10% mXCHD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20% mXCHD
Number of subjects: 30

Group type: COMPARATOR
Intervention: entecavir
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy group
Number of subjects: 30
Study: 25222572

Group type: EXPERIMENTAL
Intervention: Fish aquarium animal‐assisted therapy (FA‐AAT)
Number of subjects: 69
Study: 22609989

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective nerve root block
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoroscopy-guided transforaminal block
Number of subjects: 120
Study: 21316914

Group type: EXPERIMENTAL
Intervention: Prewarmed operating room at 24 °C
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control operating room at 17 °C
Number of subjects: 66
Study: 19931151

Group type: EXPERIMENTAL
Intervention: Topical tetracaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16784341

Group type: EXPERIMENTAL
Intervention: Primed with disliked outgroup (gay men)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primed with 'elderly'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Primed with 'youth'
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accessibility of a primed category
Number of subjects: 0
Study: 15085492

Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf) 100 mg/kg
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Poractant alfa (Curosurf) 200 mg/kg
Number of subjects: 293

Group type: COMPARATOR
Intervention: Beractant (Survanta) 100 mg/kg
Number of subjects: 293
Study: 11420324

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2 mg/kg ketamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 16